Biophytis files a patent application and strengthens its intellectual property in obesity

Biophytis announces the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial.

This new patent application, which is expected to be granted as soon as 2025, will strengthen BIO101’s (20-hydroxyecdysone) position in the treatment of obesity in combination with GLP-1 RAs. This new patent will extend the exclusivity period of BIO101 (20-hydroxyecdysone) in this indication until 2044.

Stanislas Veillet, CEO de Biophytis comments: “This patent application completes Biophytis’ patent portfolio covering its lead drug candidate. This portfolio comprises 14 patent families, including 42 issued patents and 39 patents pending, and covers the main regions of the world, in particular Europe, the United States, Japan and major countries such as Brazil and China. This patent will strengthen our intellectual property in the now key area of obesity.”

With promising results in obesity from preclinical studies and in the SARA-INT phase 2 study, BIO101 (20-hydroxyecdysone) has demonstrated its potential to become the molecule of choice for preserving muscle function in patients suffering from obesity treated with GLP-1 RAs.
Subject to regulatory approvals, the drug candidate could help address a critical medical problem, while positioning Biophytis in a large and fast-growing market. With an estimated market size of $6 billion in 2023 and an estimated average annual growth rate expected around 42%, the addressable market for the treatment of obesity is set to reach $100 billion by 2030 (source: Goldman Sachs Research).